Protagonist Therapeutics
PTGX
273 hedge funds and large institutions have $3.92B invested in Protagonist Therapeutics in 2025 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 119 increasing their positions, 75 reducing their positions, and 49 closing their positions.
59% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 75
25% more capital invested
Capital invested by funds: $3.14B → $3.92B (+$780M)
8.6% more ownership
Funds ownership: 105.9% → 114.5% (+8.6%)
4% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 49
0% more funds holding in top 10
Funds holding in top 10: 14 → 14 (0)
1% less funds holding
Funds holding: 275 → 273 (-2)
12% less call options, than puts
Call options by funds: $18.4M | Put options by funds: $20.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$103M |
| 2 |
CC
Commodore Capital
New York
|
+$51.6M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$35.9M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$30.5M |
| 5 |
Holocene Advisors
New York
|
+$25.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Focus Partners Wealth
Boston,
Massachusetts
|
-$21M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$18.5M |
| 3 |
AGP
Artia Global Partners
Miami,
Florida
|
-$14.9M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$13.2M |
| 5 |
EP
Eversept Partners
New York
|
-$12.9M |
PTGX Hedge Fund Activity: Q2 2025 in Review
273 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2025, worth a combined $3.92B — up 25% from $3.14B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new PTGX positions and 49 closed out — a net gain of 2 holders — while 119 added to existing stakes and 75 trimmed.
The largest buyer was UBS Group, adding an estimated $103M. The largest seller was Focus Partners Wealth, exiting entirely with an estimated $21M sold.
- 273 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2025, down from 275 in Q1 2025.
- Funds reported $3.92B of Protagonist Therapeutics stock for Q2 2025, up 25% quarter-over-quarter.
- 51 funds opened new Protagonist Therapeutics positions in Q2 2025 and 49 closed out, a net change of +2 holders.
- The largest Protagonist Therapeutics buyer in Q2 2025 was UBS Group, an estimated $103M added.
- The largest Protagonist Therapeutics seller in Q2 2025 was Focus Partners Wealth, an estimated $21M sold.
Based on aggregated 13F filings for Q2 2025.